Prognostic

Revolutionizing prognostic testing with advanced precision and personalized approaches

At Castle Biosciences, we believe that each patient's journey is unique. Prognostic testing provides information about the future course of the patient's disease, which can help clinicians tailor treatment plans and interventions to improve health outcomes. Our prognostic tests go beyond traditional diagnostic approaches, providing physicians with a comprehensive understanding of disease aggressiveness, recurrence risk and treatment response.

DecisionDx-Melanoma

Provides comprehensive, personalized, genomic tumor information to guide management for patients with cutaneous melanoma

DecisionDx-SCC

Identifies the risk of metastasis in patients with squamous cell carcinoma (SCC) and one or more risk factors

DecisionDx-UM

Provides comprehensive profiling for evaluating metastatic risk in uveal melanoma

TissueCypher

Predicts individual risk of progression to esophageal cancer in Barrett’s esophagus